Innocoll Holdings PLC (NASDAQ: INNL) and Sagent Pharmaceuticals (NASDAQ:SGNT) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, risk, valuation, analyst recommendations and institutional ownership.

Risk & Volatility

Innocoll Holdings PLC has a beta of -0.3, indicating that its share price is 130% less volatile than the S&P 500. Comparatively, Sagent Pharmaceuticals has a beta of 1.66, indicating that its share price is 66% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and price targets for Innocoll Holdings PLC and Sagent Pharmaceuticals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Innocoll Holdings PLC 0 3 1 0 2.25
Sagent Pharmaceuticals 0 0 0 0 N/A

Innocoll Holdings PLC presently has a consensus target price of $4.50, suggesting a potential upside of 91.49%. Given Innocoll Holdings PLC’s higher possible upside, equities analysts clearly believe Innocoll Holdings PLC is more favorable than Sagent Pharmaceuticals.

Profitability

This table compares Innocoll Holdings PLC and Sagent Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Innocoll Holdings PLC -1,051.20% N/A -138.53%
Sagent Pharmaceuticals -0.72% -0.81% -0.59%

Insider and Institutional Ownership

34.2% of Innocoll Holdings PLC shares are held by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Innocoll Holdings PLC and Sagent Pharmaceuticals’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Innocoll Holdings PLC N/A N/A N/A ($1.67) -1.41
Sagent Pharmaceuticals N/A N/A N/A ($0.76) -28.59

Sagent Pharmaceuticals is trading at a lower price-to-earnings ratio than Innocoll Holdings PLC, indicating that it is currently the more affordable of the two stocks.

Innocoll Holdings PLC Company Profile

Innocoll Holdings Public Limited Company is a commercial-stage specialty pharmaceutical and medical device company with late-stage development programs. The Company operates through the segment of manufacture and sale of collagen-based pharmaceutical products. It utilizes collagen-based technology platform to develop its biodegradable and bioresorbable products and product candidates, which can be broken down by the body without the need for surgical removal or applied topically. Using its processes at its manufacturing facility, it derives and purifies bovine and equine collagen and then utilizes its technology platform to incorporate the purified collagen into its topical and implantable products. Its lead product candidates are XaraColl for the treatment of post-operative pain and Cogenzia for the treatment of diabetic foot infections. Its marketed products include CollaGUARD, Collatamp, Septocoll and RegenePro. It has initiated its Phase III efficacy trials for Cogenzia.

Sagent Pharmaceuticals Company Profile

Sagent Pharmaceuticals, Inc. is a specialty and generic pharmaceutical company. The Company is a provider of pharmaceuticals to the hospital market, which it sells primarily throughout North America. It is focused on developing, manufacturing, sourcing and marketing injectable pharmaceutical products to the hospital market. It operates through two segments: Sagent US, consisting of the Company’s operations in the United States and the Sagent (China) Pharmaceuticals Co. Ltd. (SCP) manufacturing facility, and Omega, which is focused on the Canadian and international markets. It offers a range of products across anti-infective, oncology and critical care indications in a range of presentations, including single and multi-dose vials, pre-filled ready-to-use syringes and premix bags. Its Sagent US product portfolio includes approximately 60 marketed products that it offers in over 180 presentations, and its Omega segment offers over 50 products.

Receive News & Ratings for Innocoll Holdings PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innocoll Holdings PLC and related companies with MarketBeat.com's FREE daily email newsletter.